Industry Trend Analysis - 2018 Will See Increased CAR-T Development Activity - FEB 2018

BMI View: The CAR-T market will gain momentum over 2018 after the first two products gained approval in 2017. Further companies will release mid-to-late stage data, supporting filing and approval. Celgene will likely enter the market next through its partnerships, and be able to capitalise on its haematological cancer heritage to claim a stake.

The 59th Annual Meeting of the American Society of Hematology (ASH), held in December, was primarily focused on developments in the CAR-T sector. 2017 saw the first approvals of CAR-T products, and data released at ASH 2017 build upon this momentum. The next wave of CAR-T approvals will likely occur in 2018 and 2019, and will be differentiated by their targets. This will lead to a highly competitive market, with early movers gaining the greatest revenue growth.

Novartis Establishes Kymriah As Market Leader

CAR-T Market Will Be Competitive
Selected CAR-T Product Revenues (USDmn)
f = forecast. Source: Bloomberg, BMI

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial